Christiane Pauli-Magnus

Summary

Affiliation: University Hospital
Country: Switzerland

Publications

  1. ncbi Enterohepatic transport of bile salts and genetics of cholestasis
    Christiane Pauli-Magnus
    Division of Clinical Pharmacology and Toxicology, University Hospital Zurich, , E RAE 09, 8091 Zurich, Switzerland
    J Hepatol 43:342-57. 2005
  2. ncbi Hepatocellular transporters and cholestasis
    Christiane Pauli-Magnus
    Division of Clinical Pharmacology and Toxicology, University Hospital Zurich, Zurich, Switzerland
    J Clin Gastroenterol 39:S103-10. 2005
  3. ncbi Functional implications of genetic polymorphisms in the multidrug resistance gene MDR1 (ABCB1)
    Christiane Pauli-Magnus
    Division of Clinical Pharmacology, Department of Internal Medicine, University Hospital Zurich, Zurich, Switzerland
    Pharm Res 21:904-13. 2004
  4. ncbi BSEP and MDR3 haplotype structure in healthy Caucasians, primary biliary cirrhosis and primary sclerosing cholangitis
    Christiane Pauli-Magnus
    Division of Clinical Pharmacology and Toxicology, University Hospital Zurich, Ramistrasse 100, A 8091 Zurich, Switzerland
    Hepatology 39:779-91. 2004
  5. ncbi Sequence analysis of bile salt export pump (ABCB11) and multidrug resistance p-glycoprotein 3 (ABCB4, MDR3) in patients with intrahepatic cholestasis of pregnancy
    Christiane Pauli-Magnus
    Department of Internal Medicine, University Hospital Zurich, Zurich Switzerland
    Pharmacogenetics 14:91-102. 2004
  6. ncbi Mutations and polymorphisms in the bile salt export pump and the multidrug resistance protein 3 associated with drug-induced liver injury
    Carmen Lang
    Division of Clinical Pharmacology and Toxicology, University Hospital Zurich, Switzerland
    Pharmacogenet Genomics 17:47-60. 2007
  7. ncbi Impaired expression and function of the bile salt export pump due to three novel ABCB11 mutations in intrahepatic cholestasis
    Johannes Noe
    Division of Clinical Pharmacology and Toxicology, Department of Internal Medicine, University Hospital Zurich, Ramistrasse 100, E RAE 09, 8091 Zurich, Switzerland
    J Hepatol 43:536-43. 2005
  8. ncbi Increased susceptibility for intrahepatic cholestasis of pregnancy and contraceptive-induced cholestasis in carriers of the 1331T>C polymorphism in the bile salt export pump
    Yvonne Meier
    Division of Clinical Pharmacology and Toxicology, Department of Internal Medicine, University Hospital Zurich, Zurich, Switzerland
    World J Gastroenterol 14:38-45. 2008
  9. ncbi Pharmacogenetics of hepatocellular transporters
    Christiane Pauli-Magnus
    Department of Medicine, University Hospital, Zurich, Switzerland
    Pharmacogenetics 13:189-98. 2003
  10. ncbi Incidence of drug-induced liver injury in medical inpatients
    Yvonne Meier
    Division of Clinical Pharmacology and Toxicology, Department of Medicine, University Hospital Zurich, CH-8091, , Switzerland
    Eur J Clin Pharmacol 61:135-43. 2005

Collaborators

Detail Information

Publications18

  1. ncbi Enterohepatic transport of bile salts and genetics of cholestasis
    Christiane Pauli-Magnus
    Division of Clinical Pharmacology and Toxicology, University Hospital Zurich, , E RAE 09, 8091 Zurich, Switzerland
    J Hepatol 43:342-57. 2005
  2. ncbi Hepatocellular transporters and cholestasis
    Christiane Pauli-Magnus
    Division of Clinical Pharmacology and Toxicology, University Hospital Zurich, Zurich, Switzerland
    J Clin Gastroenterol 39:S103-10. 2005
    ..This overview summarizes the physiologic function and regulation of human hepatobiliary transport systems and discusses the impact of their genetic variations for the pathophysiology of different cholestatic syndromes...
  3. ncbi Functional implications of genetic polymorphisms in the multidrug resistance gene MDR1 (ABCB1)
    Christiane Pauli-Magnus
    Division of Clinical Pharmacology, Department of Internal Medicine, University Hospital Zurich, Zurich, Switzerland
    Pharm Res 21:904-13. 2004
    ..This review will focus on the impact of genetic variation in MDR1 on expression and function of P-glycoprotein and the implications of this variation for drug therapy and disease risk...
  4. ncbi BSEP and MDR3 haplotype structure in healthy Caucasians, primary biliary cirrhosis and primary sclerosing cholangitis
    Christiane Pauli-Magnus
    Division of Clinical Pharmacology and Toxicology, University Hospital Zurich, Ramistrasse 100, A 8091 Zurich, Switzerland
    Hepatology 39:779-91. 2004
    ..Although an impact of rare variants on BSEP and MDR3 function cannot be ruled out, our data do not support a strong role of BSEP and MDR3 genetic variations in the pathogenesis of PBC and PSC...
  5. ncbi Sequence analysis of bile salt export pump (ABCB11) and multidrug resistance p-glycoprotein 3 (ABCB4, MDR3) in patients with intrahepatic cholestasis of pregnancy
    Christiane Pauli-Magnus
    Department of Internal Medicine, University Hospital Zurich, Zurich Switzerland
    Pharmacogenetics 14:91-102. 2004
    ....
  6. ncbi Mutations and polymorphisms in the bile salt export pump and the multidrug resistance protein 3 associated with drug-induced liver injury
    Carmen Lang
    Division of Clinical Pharmacology and Toxicology, University Hospital Zurich, Switzerland
    Pharmacogenet Genomics 17:47-60. 2007
    ..The aim of this study was therefore to describe the extent of genetic variability in ABCB11 and ABCB4 in patients with drug-induced liver injury and to in vitro functionally characterize newly detected ABCB11 mutations and polymorphisms...
  7. ncbi Impaired expression and function of the bile salt export pump due to three novel ABCB11 mutations in intrahepatic cholestasis
    Johannes Noe
    Division of Clinical Pharmacology and Toxicology, Department of Internal Medicine, University Hospital Zurich, Ramistrasse 100, E RAE 09, 8091 Zurich, Switzerland
    J Hepatol 43:536-43. 2005
    ..We functionally characterized novel ABCB11 mutations encountered in two patients with a PFIC2 and a BRIC2 phenotype, respectively...
  8. ncbi Increased susceptibility for intrahepatic cholestasis of pregnancy and contraceptive-induced cholestasis in carriers of the 1331T>C polymorphism in the bile salt export pump
    Yvonne Meier
    Division of Clinical Pharmacology and Toxicology, Department of Internal Medicine, University Hospital Zurich, Zurich, Switzerland
    World J Gastroenterol 14:38-45. 2008
    ....
  9. ncbi Pharmacogenetics of hepatocellular transporters
    Christiane Pauli-Magnus
    Department of Medicine, University Hospital, Zurich, Switzerland
    Pharmacogenetics 13:189-98. 2003
    ....
  10. ncbi Incidence of drug-induced liver injury in medical inpatients
    Yvonne Meier
    Division of Clinical Pharmacology and Toxicology, Department of Medicine, University Hospital Zurich, CH-8091, , Switzerland
    Eur J Clin Pharmacol 61:135-43. 2005
    ..Incidences of DILI were highest for antineoplastic agents and tuberculostatics. DILI is frequently missed and, therefore, DILI detection by diagnoses will result in misleadingly low incidence rates...
  11. ncbi Hepatobiliary transporters and drug-induced cholestasis
    Christiane Pauli-Magnus
    Division of Clinical Pharmacology and Toxicology, University Hospital Zurich, Zurich, Switzerland
    Hepatology 44:778-87. 2006
    ..This review summarizes current knowledge about the function of hepatobiliary uptake and efflux systems and discusses factors that might predispose to drug-induced cholestasis...
  12. ncbi Interindividual variability of canalicular ATP-binding-cassette (ABC)-transporter expression in human liver
    Yvonne Meier
    Division of Clinical Pharmacology and Toxicology, Department of Medicine, University Hospital, Zurich, Switzerland
    Hepatology 44:62-74. 2006
    ..Furthermore, data suggest a polymorphic transporter expression pattern, which might constitute a risk factor for the development of acquired forms of cholestatic liver diseases...
  13. ncbi Adverse drug events caused by medication errors in medical inpatients
    Beat Hardmeier
    Division of Clinical Pharmacology and Toxicology, Department of Medicine, University Hospital, , Switzerland
    Swiss Med Wkly 134:664-70. 2004
    ..In contrast, eADEs accounted for 30% of ADE-related hospital admissions. Hence, in medical inpatients, eADEs represented a small fraction of total incident ADEs, whereas they contributed significantly to hospital admissions...
  14. ncbi Effect of ritonavir on the pharmacokinetics of the benzimidazoles albendazole and mebendazole: an interaction study in healthy volunteers
    Natascia Corti
    Division of Clinical Pharmacology and Toxicology, University Hospital Zurich, Ramistrasse 100, 8091 Zurich, Switzerland
    Eur J Clin Pharmacol 65:999-1006. 2009
    ..The aim of the present study was to investigate potential drug interactions between the benzimidazoles albendazole and mebendazole and the potent CYP3A4 inhibitor ritonavir...
  15. ncbi Pharmacokinetics of high doses of intramuscular and oral heroin in narcotic addicts
    François Girardin
    Division of Clinical Pharmacology and Toxicology, Department of Medicine, University Hospital, Zurich, Switzerland
    Clin Pharmacol Ther 74:341-52. 2003
    ..Therefore we characterized the pharmacokinetics of intramuscular and oral diacetylmorphine in the high dose range usually required in narcotic addicts...
  16. ncbi No effect of MDR1 C3435T variant on loperamide disposition and central nervous system effects
    Christiane Pauli-Magnus
    Department of Biopharmaceutical Sciences, University of California, San Francisco, CA 94143 0446, USA
    Clin Pharmacol Ther 74:487-98. 2003
    ..The aim of this study was to investigate the effect of this polymorphism on disposition and brain entry of the P-glycoprotein substrate loperamide...
  17. ncbi Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene
    Deanna L Kroetz
    Department of Biopharmaceutical Sciences, University of California San Francisco, 513 Parnassus Avenue, San Francisco, CA 94143 0446, USA
    Pharmacogenetics 13:481-94. 2003
    ....
  18. ncbi MDR1 reference sequence and reference function
    Christiane Pauli-Magnus
    Clin Pharmacol Ther 72:100-1. 2002